Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Pyrazinamide

FDA-approved product (tablet, oral), marketed as Pyrazinamide.

Registered studies
50+
Lab records
45
Pathogens at ≥40%
0 of 4

Chemical structure

Chemical structure of Pyrazinamide
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Pulmonary tuberculosis
  • Tuberculosis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other drugs for treatment of tuberculosis
FDA pharmacologic class
Antimycobacterial FDA label ↗
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J04AK01; FDA class Antimycobacterial

Repurposing investigation

Pyrazinamide is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA17.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli15.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae7.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis13.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • M. tuberculosis: measured active in 2 of 45 lab records
Open Pyrazinamide in ChEMBL Registered studies below
Show the 45 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-4.3 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-5.1 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-4.6 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-4.5 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Pyrazinamide with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • AIPH-TB: AI-Optimised Pyrazinamide-Hydroxychloroquine vs Standard RIPE for Drug-Sensitive Pulmonary Tuberculosis - A Phase II RCT

    NCT07467252 · start 2026-09

    Registered record
    Registry ID
    NCT07467252
    Conditions
    Pulmonary Tuberculosis
    Interventions
    Pyrazinamide and Hydroxychloroquine (AI-Optimised); Standard RIPE Regimen (Rifampicin, Isoniazid, Pyrazinamide, Ethambutol)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-09
    Completion
    2028-06
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPulmonary Tuberculosis
    InterventionPyrazinamide and Hydroxychloroquine (AI-Optimised); Standard RIPE Regimen (Rifampicin, Isoniazid, Pyrazinamide, Ethambutol)
    PhasePhase 2
    Registry statusNot yet recruiting

  • Short-Course Regimens for DS-PTB in AIDS Patients

    NCT07608172 · start 2026-05-25

    Registered record
    Registry ID
    NCT07608172
    Conditions
    Tuberculosis in HIV-infected Individuals; Drug Susceptible Pulmonary Tuberculosis
    Interventions
    2HPMZ/2HPM; 2HRZE/4HR
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Not yet recruiting
    Start
    2026-05-25
    Completion
    2028-12-31
    Enrolment
    148

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis in HIV-infected Individuals; Drug Susceptible Pulmonary Tuberculosis
    Intervention2HPMZ/2HPM; 2HRZE/4HR
    PhaseNot applicable
    Registry statusNot yet recruiting

  • Evaluating a Shorter, Rifampicin-Based Treatment for People With Less Severe Tuberculosis Disease

    NCT07118696 · start 2026-02-01

    Registered record
    Registry ID
    NCT07118696
    Conditions
    Pulmonary TB
    Interventions
    Extra 600mg of Rifampicin; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Not yet recruiting
    Start
    2026-02-01
    Completion
    2030-01-31
    Enrolment
    1,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPulmonary TB
    InterventionExtra 600mg of Rifampicin; Placebo
    PhasePhase 3
    Registry statusNot yet recruiting

  • ATORvastatin in Pulmonary TUBerculosis: a POPulation PharmacoKinetics -PharmacoDynamics Sub-study (ATORTUB popPK-PD)

    NCT07303699 · start 2026-01-03

    Registered record
    Registry ID
    NCT07303699
    Conditions
    Pulmonary Tuberculosis (TB)
    Interventions
    Atorvastatin 20 mg; Atorvastatin 40 mg; Atorvastatin 60 mg; Fixed dose combination of Rifampicin (R) Isoniazid (H) Pyrazinamid (Z) Ethambutol (E)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2026-01-03
    Completion
    2028-03-30
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPulmonary Tuberculosis (TB)
    InterventionAtorvastatin 20 mg; Atorvastatin 40 mg; Atorvastatin 60 mg; Fixed dose combination of Rifampicin (R) Isoniazid (H) Pyrazinamid (Z) Ethambutol (E)
    PhasePhase 2
    Registry statusRecruiting

  • Phase 2 Trial to Evaluate the Safety and Tolerability and Early Bactericidal Activity of RESP30TB in Tuberculosis

    NCT07073638 · start 2025-10-13

    Registered record
    Registry ID
    NCT07073638
    Conditions
    Pulmonary Tuberculoses
    Interventions
    RESP30TB; HRZE (Rifampicin, Isoniazid, Pyrazinamide, Ethambutol combination)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2025-10-13
    Completion
    2026-11-15
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPulmonary Tuberculoses
    InterventionRESP30TB; HRZE (Rifampicin, Isoniazid, Pyrazinamide, Ethambutol combination)
    PhasePhase 2
    Registry statusRecruiting

  • A PAN-USR TB Multi-Center Trial

    NCT06905522 · start 2025-06-18

    Registered record
    Registry ID
    NCT06905522
    Conditions
    Pulmonary Tuberculosis
    Interventions
    Bedaquiline (B); Sitafloxacin (S); Linezolid (L); Pyrazinamide (Z); Isoniazid (H); Rifampicin (R); Ethambutol (E); Moxifloxacin (M); Pretomanid (Pa)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2025-06-18
    Completion
    2029-12
    Enrolment
    610

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPulmonary Tuberculosis
    InterventionBedaquiline (B); Sitafloxacin (S); Linezolid (L); Pyrazinamide (Z) +5 more
    PhasePhase 3
    Registry statusRecruiting

  • A Study of the Early Effects, Safety, and Acceptability of Oral Alpibectir in Combination With Ethionamide

    NCT06748937 · start 2025-03-03

    Registered record
    Registry ID
    NCT06748937
    Conditions
    Tuberculosis
    Interventions
    Alpibectir 45 mg once daily (OD) plus Ethionamide 125 mg OD; Alpibectir 45 mg OD plus Ethionamide 250 mg OD; Isoniazid, rifampicin, pyrazinamide and ethambutol fixed dose combination, weight based; Alpibectir 45 mg OD plus Ethionamide 250 mg OD plus Rifampicin 10 mg/kg OD plus Ethambutol 20 mg/kg OD plus Pyrazinamide 25 mg/kg OD
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2025-03-03
    Completion
    2026-03-30
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis
    InterventionAlpibectir 45 mg once daily (OD) plus Ethionamide 125 mg OD; Alpibectir 45 mg OD plus Ethionamide 250 mg OD; Isoniazid, rifampicin, pyrazinamide and ethambutol fixed dose combination, weight based; Alpibectir 45 mg OD plus Ethionamide 250 mg OD plus Rifampicin 10 mg/kg OD plus Ethambutol 20 mg/kg OD plus Pyrazinamide 25 mg/kg OD
    PhasePhase 2
    Registry statusRecruiting

  • Registry on the Effectiveness and Safety of the 9-month MDR-END Treatment Regimen in Korean Patients with FQ-sensitive MDR-TB (MDR-END Registry)

    NCT06674291 · start 2024-11-30

    Registered record
    Registry ID
    NCT06674291
    Conditions
    Tuberculosis, Multidrug-Resistant
    Interventions
    No intervention (observational study)
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Not yet recruiting
    Start
    2024-11-30
    Completion
    2028-12-31
    Enrolment
    222

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis, Multidrug-Resistant
    InterventionNo intervention (observational study)
    PhaseNot recorded
    Registry statusNot yet recruiting

  • Intensified Short Course Regimen for TBM in Adults

    NCT05917340 · start 2024-03

    Registered record
    Registry ID
    NCT05917340
    Conditions
    Tuberculous Meningitis
    Interventions
    High dose rifampicin (25mg/kg); Moxifloxacin 400mg; Aspirin 150 mg; Isoniazid; Pyrazinamide; Steroid; Rifampicin; HRZE; HRE
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Not yet recruiting
    Start
    2024-03
    Completion
    2027-09
    Enrolment
    372

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculous Meningitis
    InterventionHigh dose rifampicin (25mg/kg); Moxifloxacin 400mg; Aspirin 150 mg; Isoniazid +5 more
    PhasePhase 3
    Registry statusNot yet recruiting

  • Pharmacokinetics and Safety of Double-dose Dolutegravir When Used With Rifapentine for HIV-associated Tuberculosis

    NCT05630872 · start 2024-02-13

    Registered record
    Registry ID
    NCT05630872
    Conditions
    HIV-associated Tuberculosis
    Interventions
    Dolutegravir (DTG) 50 mg orally BID (~12 hours apart) plus TDF/3TC; DTG 50 mg orally QD plus TDF/3TC; 2HPZM; 2HPM
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2024-02-13
    Completion
    2025-11-12
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-associated Tuberculosis
    InterventionDolutegravir (DTG) 50 mg orally BID (~12 hours apart) plus TDF/3TC; DTG 50 mg orally QD plus TDF/3TC; 2HPZM; 2HPM
    PhasePhase 2
    Registry statusCompleted

  • ATORvastatin in Pulmonary TUBerculosis

    NCT06199921 · start 2024-01-03

    Registered record
    Registry ID
    NCT06199921
    Conditions
    Pulmonary Tuberculosis; Tuberculosis; Koch's Disease
    Interventions
    Atorvastatin 20mg; Atorvastatin 40mg; Atorvastatin 60mg; Fixed dose combination of Rifampicin (R) Isoniazid (H) Pyrazinamide (Z) Ethambutol (E)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2024-01-03
    Completion
    2026-09-30
    Enrolment
    440

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPulmonary Tuberculosis; Tuberculosis; Koch's Disease
    InterventionAtorvastatin 20mg; Atorvastatin 40mg; Atorvastatin 60mg; Fixed dose combination of Rifampicin (R) Isoniazid (H) Pyrazinamide (Z) Ethambutol (E)
    PhasePhase 2
    Registry statusRecruiting

  • Short Course Regimen in Low Risk Active Tuberculosis- a Multicenter, Randomized, Active-controlled, Trial

    NCT06727864 · start 2024-01-01

    Registered record
    Registry ID
    NCT06727864
    Conditions
    Pulmonary Tuberculosis
    Interventions
    4-month regimen (2HERZ/2HRE); 6-month (2HERZ/4HRE)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2024-01-01
    Completion
    2028-12-31
    Enrolment
    270

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPulmonary Tuberculosis
    Intervention4-month regimen (2HERZ/2HRE); 6-month (2HERZ/4HRE)
    PhasePhase 3
    Registry statusRecruiting

  • Efficacy and Safety Evaluation of Two to Four Months of Treatment With the Combination Regimens of DBOS and PBOS in Adults With Pulmonary Tuberculosis

    NCT05971602 · start 2023-07-26

    Registered record
    Registry ID
    NCT05971602
    Conditions
    Pulmonary Tuberculosis
    Interventions
    Delamanid, Bedaquiline, OPC-167832, and Sutezolid (DBOS); Pretomanid, Bedaquiline, OPC-167832, and Sutezolid (PBOS); Isoniazid, Rifampicin, Pyrazinamide, Ethambutol (HRZE); Pretomanid or Delamanid, Bedaquiline, OPC-167832, and Sutezolid (XBOS); Isoniazid and Rifampicin (HR)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2023-07-26
    Completion
    2025-02-06
    Enrolment
    93

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPulmonary Tuberculosis
    InterventionDelamanid, Bedaquiline, OPC-167832, and Sutezolid (DBOS); Pretomanid, Bedaquiline, OPC-167832, and Sutezolid (PBOS); Isoniazid, Rifampicin, Pyrazinamide, Ethambutol (HRZE); Pretomanid or Delamanid, Bedaquiline, OPC-167832, and Sutezolid (XBOS) +1 more
    PhasePhase 2
    Registry statusTerminated

  • Doxycycline Host-directed Therapy to Improve Lung Function and Decrease Tissue Destruction in Pulmonary Tuberculosis

    NCT05473520 · start 2023-05-24

    Registered record
    Registry ID
    NCT05473520
    Conditions
    Tuberculosis; Acute Coronary Syndrome; Pulmonary Hypertension (Diagnosis)
    Interventions
    Doxycycline; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2023-05-24
    Completion
    2030-01-31
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis; Acute Coronary Syndrome; Pulmonary Hypertension (Diagnosis)
    InterventionDoxycycline; Placebo
    PhasePhase 3
    Registry statusRecruiting

  • Evaluation of the Early Bactericidal Activity of Tedizolid and Linezolide Against Mycobacterium Tuberculosis (TEDITUB)

    NCT05534750 · start 2023-04-20

    Registered record
    Registry ID
    NCT05534750
    Conditions
    Tuberculosis; Multidrug Resistant Tuberculosis
    Interventions
    Tedizolid arm (SIVEXTRO®); Linezolid arm (ZYVOXID®); Standard quadruple therapy arm
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2023-04-20
    Completion
    2026-05
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis; Multidrug Resistant Tuberculosis
    InterventionTedizolid arm (SIVEXTRO®); Linezolid arm (ZYVOXID®); Standard quadruple therapy arm
    PhasePhase 2
    Registry statusRecruiting